| OA12.05 | Improved in vitro expression and in vivo immunogenicity of a candidate MVA-vectored HIV-1 vaccine compared to SAAVI MVA-C | Oral Abstract Session | Novel vaccine and other prevention approaches |
| OA13.01 | Implementing a rapid response to the COVID-19 global pandemic in MTN-034/REACH: an HIV prevention trial among adolescent girls and young women in Africa | Oral Abstract Session | Ethics in HIV prevention research |
| OA13.02 | Social, economic, mental health and medical care impacts of COVID-19 in a US cohort of sex and gender diverse adolescents and young adults at-risk for HIV | Oral Abstract Session | Behavioural and social science research |
| OA13.03 | Acceptability of telemedicine and HIV self-test among PrEP users during the COVID-19 pandemic in Brazil | Oral Abstract Session | Implementation science, including structural interventions, PrEP & VMMC |
| OA13.04 | The COVID-19 pandemic and transition to telehealth: appointment attendance and patient perspectives at an adult HIV clinic | Oral Abstract Session | Behavioural and social science research |
| OA13.05LB | Utilizing a robust HIV prevention community engagement framework to engage communities in COVID-19 prevention efforts | Oral Abstract Session | Community engagement in prevention research |
| OA14.01 | Improved killing of HIV-infected cells by a combination of three neutralizing and non-neutralizing antibodies | Oral Abstract Session | Therapeutic vaccines, viral reservoirs and eradication/remission |
| OA14.02 | Unprimed CD8+ lymphocytes promote the maintenance of HIV latency in CD4+ T cells | Oral Abstract Session | Therapeutic vaccines, viral reservoirs and eradication/remission |
| OA14.03 | Analysis of the early responses to HIV-1 in matched treatment naïve individuals reveals early soluble proteins that are associated with in vivo virus control | Oral Abstract Session | Innate and trained immunity |
| OA14.04 | Targeting Sphingosine-1-phosphate signaling prevents cell-to-cell transmission of HIV-1 | Oral Abstract Session | Therapeutic vaccines, viral reservoirs and eradication/remission |